Home / Health / India Boosts Oversight of Gene Therapies
India Boosts Oversight of Gene Therapies
2 Jul
Summary
- Stem cell and CAR-T therapies now under stricter regulation.
- Gene therapies for genetic disorders and cancers face new rules.
- Xenografts for cardiology and orthopedics also included.
The Central government has amended the Drugs Rules, 1945, to strengthen regulatory oversight of emerging medical technologies. This amendment brings stem cell-derived products, gene therapeutic products, and xenografts under the Centrally Licence Approving Authority (CLAA) framework. This move aims to ensure enhanced scrutiny for complex and rapidly evolving medical sciences.
Products like stem cell-based regenerative treatments and CAR-T cell therapies, increasingly used for blood cancers such as leukemias and lymphomas, will now have joint regulatory supervision. Gene therapeutic products, used for genetic disorders and cancers, and xenografts, such as animal heart valves for transplantation, also fall under the new regulations.
The inclusion under the CLAA framework will facilitate joint oversight by Central and State Licensing Authorities, ensuring uniform regulatory standards nationwide. This initiative reinforces India's regulatory framework, aligning it with scientific advancements and global best practices, thereby prioritizing patient safety.
